河南省脑靶向生物纳米药物重点实验室
  河南省纳米生物医学国际联合实验室
 
当前位置: 首页/科研成果/文章/2020/正文
 

Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy. 

Yanjie Liu,# Yan Zou,# Chan Feng,# Albert Lee, Jinlong Yin, Roger Chung, Jong Bea Park, Helen Rizos, Wei Tao, Meng Zheng,* Omid C. Farokhzad,* and Bingyang Shi*

Nano Letters. 2020, 20, 1637–1646. (IF=11.189)

ABSTRACT: 

Nanotechnology-based RNA interference (RNAi) has shown great promise in overcoming the limitations of traditional clinical treatments for glioblastoma (GBM). However, because of the complexity of brain physiology, simple blood−brain barrier (BBB) penetration or tumor-targeting strategies cannot entirely meet the demanding requirements of different therapeutic delivery stages. Herein, we developed a charge conversional biomimetic nanoplatform with a three-layer core−shell structure to programmatically overcome persistent obstacles in siRNA delivery to GBM. The resulting nanocomplex presents good biocompatibility, prolonged blood circulation, high BBB transcytosis, effective tumor accumulation, and specific uptake by tumor cells in the brain. Moreover, red blood cell membrane (RBCm) disruption and effective siRNA release can be further triggered elegantly by charge conversion from negative to positive in the endo/lysosome (pH 5.0−6.5) of tumor cells, leading to highly potent target-gene silencing with a strong anti-GBM effect. Our study provides an intelligent biomimetic nanoplatform tailored for systemically siRNA delivery to GBM, leveraging Angiopep-2 peptide-modified, immune-free RBCm and charge conversional components. Improved therapeutic efficacy, higher survival rates, and minimized systemic side effects were achieved in orthotopic U87MG-luc human glioblastoma tumor-bearing nude mice.


DOI: 10.1021/acs.nanolett.9b04683



  地址
河南省开封市
河南大学金明校区,生命科学学院
475004
 技术支持:河南科加
  联系方式
邮箱: jcbi@vip.henu.edu.cn
facebooktwitteryoutubeg+